Sanofi
Sarclisa
multiple myeloma
Resolved
29days ago
FDA decision · Jul 23, 2026
What's at stake
The FDA's approval decision on Sarclisa for multiple myeloma is due Jul 23, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 2mo ago
“The revised target action date for the FDA decision is July 23, 2026.”